Details of the Drug Reposition

General Information of This Drug (ID: DMDN4ZP)

Drug Name
Lixivaptan   DMDN4ZP
Synonyms
168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; VPA985; BF-Derm1
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hyponatraemia DISSEH6G 5C72 Phase 3 [1]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Skin infection DISVYKGN 1F28-1G0Z Phase 2 [2]
Congestive heart failure DIS32MEA BD10 Phase 2 [1]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2238).
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020550)